Michael A. Rogawski

Faculty Opinions recommendation of Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature June 28, 2021 Michael A. Rogawski

While anecdotal evidence suggests that select 5-hydroxytryptamine 2A (5-HT2A) receptor ligands, including psilocybin, may have long-lasting therapeutic effects after limited dosing in headache disorders, controlled investigations are lacking. In an exploratory double-blind, placebo-controlled, cross-over study, adults with migraine received oral placebo and psilocybin (0.143 mg/kg) in 2 test...